SAN FRANCISCO -- SK Biopharmaceuticals plans to establish a joint venture with Eurofarma, one of Latin America’s leading pharmaceutical companies, to commercialize a new AI-based epilepsy ...

SK Biopharmaceuticals CEO Lee Dong-hoon speaks at a press event on Monday announcing the joint venture formed between the Korean company and Eurofarma in San Francisco. [SK BIOPHARMACEUTICALS] SAN ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As global markets continue to react to political developments and economic indicators, major indexes like the S&P 500 have reached new highs amid optimism over potential trade deals and AI investments ...

Meanwhile, another Korean biotech, SK Biopharmaceuticals, signed a deal with Brazil’s Eurofarma to set up a joint venture in the U.S. to develop an epilepsy treatment platform based on ...

SK hynix shares tumble after DeepSeek’s low-cost AI model shakes chip market ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

1 Day 326030 0.46% DJIA 0.65% S&P 500 -1.46% Health Care/Life Sciences -0.52% ...

SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American biopharma, Eurofarma, in the United ...